An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites

By M. Attia, N. Anton, Justine Wallyn, Ziad Omran, T. Vandamme. The Journal of pharmacy and pharmacology, 2019

779 citations recorded by the source corpus.

This review highlights both the physicochemical characteristics of the nanocarriers (NCs) and the physiological features of tumour microenvironment (TME) to outline what strategies undertaken to deliver the molecules of interest specifically to certain lesions. This review discusses these properties describing the convenient choice between passive and active targeting mechanisms with details, illustrated with examples of targeting agents up to preclinical research or clinical advances.

Subfields: Biomaterials, Biomedical Engineering

View Paper: https://www.semanticscholar.org/paper/afe87972d45a3931cc95859cb84e7aca640d91a5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. Sameer Quazi
2. Tomasz M. Karpinski
3. Shreelaxmi Gavas
4. Seeram Ramakrishna
5. Shivakalyani Adepu
6. S. Kundu
7. Nandana Bhardwaj
8. Benjamin S. Hsiao

In Biomedical Engineering

1. Sameer Quazi
2. Tomasz M. Karpinski
3. Shreelaxmi Gavas
4. Seeram Ramakrishna

Citations in the corpus

• Nanoparticles for Cancer Therapy: Current Progress and Challenges (2021, background): “It is the chief energy source for cell division [35] and makes the surrounding environment acidic.”
• Controlled Drug Delivery Systems: Current Status and Future Directions (2021, background): “In the active mode, the specific marker, which is expressed exclusively in the diseased cells but not in the normal cells, is targeted [75].”